Precision Health Clinical Trials

Heart Attack Research Program: Platelet Sub-Study (HARP)

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   NYU Langone Health
Recruiting

Scrub Typhus Antibiotic Resistance Trial

Condition:   Scrub Typhus
Interventions:   Drug: Doxycycline 7 days;   Drug: Doxycycline 3 days;   Drug: Azithromycin 3 days
Sponsors:   University of Oxford;   Shoklo Malaria Research Unit;   Chiangrai Prachanukroh Hospital
Recruiting

Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer

Condition:   Stage III Colorectal Cancer
Interventions:   Genetic: Gene mutations analysis;   Genetic: Gene methylation analysis;   Genetic: Gene expression analysis;   Genetic: SNP analysis;   Genetic: Protein expression analysis
Sponsor:   Renmin Hospital of Wuhan University
Not yet recruiting

Analysis of DNA Methylation in Spondyloarthritis

Conditions:   Spondylitis, Ankylosing;   Axial Spondyloarthritis;   DNA Methylation
Intervention:   Other: Blood sample
Sponsor:   Centre Hospitalier Universitaire de Besancon
Recruiting

The Epigenetic Modification in OPRM1 on Postoperative Analgesia and Side Effect Induced by Sufentanil

Condition:   Epigenetics
Interventions:   Drug: Sufentanil;   Drug: dexmedetomidine;   Drug: propofol;   Drug: Rocuronium;   Drug: sevoflurane;   Drug: remifentanil;   Drug: Parecoxib
Sponsor:   Huazhong University of Science and Technology
Recruiting

Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer.

Conditions:   Pancreas Cancer;   Melanoma
Intervention:  
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Conditions:   Malignant Solid Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent WHO Grade 2 Glioma;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Wilms Tumor
Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group
Recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Primary Central Nervous System Neoplasm;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
Intervention:   Drug: Olaparib
Sponsor:   National Cancer Institute (NCI)
Recruiting

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting

Clinical Study of Microchimerism and cfDNA as Biomarkers for Acute Rejection After Organ Transplantation

Condition:   Organ Transplant Rejection
Intervention:   Other: no interventions
Sponsors:   Fuzhou General Hospital;   309th Hospital of Chinese People's Liberation Army;   Tianjin First Central Hospital;   RenJi Hospital;   Fudan University;   Ruijin Hospital;   First Affiliated Hospital, Sun Yat-Sen University;   Third Affiliated Hospital, Sun Yat-Sen University;   Huazhong University of Science and Technology;   West China Hospital;   Central South University;   The Third Xiangya Hospital of Central South University;   First Affiliated Hospital Xi'an Jiaotong University;   Qianfoshan Hospital;   Wuxi People's Hospital;   Second Affiliated Hospital of Guangzhou Medical University
Recruiting

Pages